Trial Profile
A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2018
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary) ; Fingolimod
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms REVEAL
- Sponsors Biogen
- 14 Nov 2018 Results utilizing real world data from MSbase registry estimating cost-effectiveness in Spain, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 14 Nov 2018 Results utilizing real world data from MSbase registry estimating cost effectiveness in italy, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 28 Oct 2017 Results presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis